NL Upgraded to Outperform on CompX Strength, Kronos Recovery

NL Industries was upgraded to Outperform from Neutral as CompX and Kronos both project 2026 sales and margin improvement. CompX's Q2 2026 Security Products sales rose 9% year over year, unit profit increased 39% to $8.0 million, and consolidated segment profit rose 41% to $8.9 million as gross margin expanded to 36% from 32%. Kronos' restructuring lifted Q2 operating income to $37.6 million from $7.4 million and gross margin to 18% from 13%, though TiO2 pricing, FX, tariffs and raw-material costs remain risks.

Analysis

NL is a low-liquidity holding-company expression of two distinct earnings recoveries, but the market is likely to discount the durability of both until reported results strip out the non-recurring CompX cost recovery and normalize the prior customer-stocking comparison. The investable mechanism is operating leverage: sustained Security Products mix gains can support a higher standalone CIX earnings base, while each incremental improvement in KRO profitability flows to NL through its equity stake without requiring additional capital. A discount-to-look-through-NAV rerating is plausible over the next 1-3 quarters if management demonstrates that cash generation, rather than accounting earnings, is improving.

KRO is the cleaner cyclical read-through but also the principal risk to NL: titanium-dioxide markets remain structurally oversupplied, so lower feedstock costs and leaner capacity can lift margins before TiO2 prices recover, but that benefit reverses quickly if utilization falls again. KRO's cost reset may pressure less-flexible TiO2 peers such as CC, whose earnings are more exposed to a delayed pricing recovery. For CIX, tariffs and input inflation are a direct test of pricing power; failure to sustain gross margin after the one-time benefit would cap the multiple expansion.

Consensus may over-credit the headline earnings acceleration while underweighting NL's structure: holding-company discounts persist when capital allocation, tax leakage, and cash upstreaming are opaque. This is therefore a catalyst trade rather than a structural compounder. The thesis is falsified by sequential CIX margin retracement excluding one-offs, KRO returning to material unabsorbed fixed costs, or a TiO2 price decline that outpaces feedstock relief over the next two reporting periods.

Key Decisions for Investors

• Watch, do not chase NL immediately: initiate only after the next quarterly filing confirms CIX gross margin holds above its normalized pre-one-off level and KRO maintains positive operating income. Target a 3-6 month rerating from narrowing of the holding-company discount; exit on a material reduction in 2026 margin guidance.
• Prefer a small long KRO position over NL for a 1-3 month cyclical catalyst if TiO2 benchmark pricing stabilizes and feedstock costs remain contained. Size modestly given commodity beta; stop-loss trigger is renewed TiO2 price deterioration combined with rising inventory or utilization cuts.
• Use CIX as the higher-quality operating-leverage vehicle only if trading liquidity permits institutional execution. Buy following evidence that healthcare/transportation demand converts into backlog or order growth rather than distributor inventory build; risk is that normalized segment margin falls back toward historical levels once temporary cost benefits roll off.
• Avoid QBTS as a read-through: it is included in the supplied ticker set but has no discernible economic linkage to the NL/CIX/KRO thesis.